Drug Trial Radar · NCT07613684
Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Dec 20, 2024
Primary completion
Oct 9, 2025
Study completion Oct 9, 2025
Sponsor
- Lead sponsor
- Epirium Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- May 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose \[SAD\] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose \[MAD\] Phase). The SAD and MAD phases will evaluate separately non-elderly (≥ 18 to ≤ 65 years of age) and elderly (\> 65 to ≤75 years of age) healthy adult subjects.
Conditions
- Healthy Volunteers
Interventions
MF-300 SADDrug
oral capsule at doses of 75mg, 125 mg, 250 mg, 500 mg, or 800 mg
PlaceboDrug
matching placebo oral capsule
MF-300 Food EffectDrug
oral capsule at a dose of 500 mg
MF-300 MADDrug
oral capsule at doses of 75mg, 125 mg, or 200 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with treatment-emergent adverse events (TEAEs)Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
- Proportion of participants with serious adverse events (SAEs)Time frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
- Proportion of participants with any TEAE leading to premature discontinuation of study interventionTime frame: From admission on Day -1 to the Follow-up End of Study Visit (Day 7 for Part 1a, Day 13 for Part 1b, and Day 11 for Part 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site 102
Marlton, New Jersey
Site 101
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.